RunCoach, It depends on the alliances they can forge with the distributers/manufacturers that will be selling the cancer tests. If there is a provable market in overseas areas such as India, China, Australia, etc using a distribution network with a Proven track record (ex: SRL).
Then YES, the company will have an attractive multiple in it PPS.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.